% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Bochtler:125525,
      author       = {T. Bochtler$^*$ and U. Hegenbart and C. Kunz$^*$ and A.
                      Benner$^*$ and C. Kimmich and A. Seckinger and D. Hose and
                      H. Goldschmidt and M. Granzow and P. Dreger and A. D. Ho and
                      A. Jauch and S. O. Schönland},
      title        = {{P}rognostic impact of cytogenetic aberrations in {AL}
                      amyloidosis patients after high-dose melphalan: a long-term
                      follow-up study.},
      journal      = {Blood},
      volume       = {128},
      number       = {4},
      issn         = {1528-0020},
      address      = {Stanford, Calif.},
      publisher    = {HighWire Press},
      reportid     = {DKFZ-2017-01651},
      pages        = {594 - 602},
      year         = {2016},
      abstract     = {Cytogenetic aberrations detected by interphase fluorescence
                      in situ hybridization (iFISH) of plasma cells are routinely
                      evaluated as prognostic markers in multiple myeloma. This
                      long-term follow-up study aimed to assess the prognosis of
                      systemic light chain amyloidosis (AL) patients treated with
                      high-dose melphalan (HDM) chemotherapy and autologous stem
                      cell transplantation, depending on iFISH results. Therefore,
                      we analyzed a consecutive cohort of 123 AL patients
                      recruited from 2003 to 2014. HDM was safe, with only 1 of
                      123 patients dying as a result of treatment-related
                      mortality, and effective, with a complete remission (CR)
                      rate of $34\%.$ Translocation t(11;14) as the most prevalent
                      aberration $(59\%)$ led to an improved CR rate after
                      high-dose therapy $(41.2\%$ vs $20.0\%;$ P = .02),
                      translating into a prolonged hematologic event-free survival
                      (hemEFS; median, 46.1 vs 28.1 months; P = .05) and a trend
                      for better overall survival (median, not reached vs 93.7
                      months; P = .07). In multivariate analysis, t(11;14) was
                      confirmed as a favorable prognostic factor regarding hemEFS
                      along with lower values for the difference between involved
                      and uninvolved free light chains. Conversely, deletion
                      13q14, gain of 1q21, and hyperdiploidy had no significant
                      prognostic impact. The high-risk cytogenetic aberrations
                      t(4;14), t(14;16), and del(17p13) conferred an unfavorable
                      prognosis, although statistical significance was reached
                      only for univariate CR analysis in this small group of 9
                      patients. Thus, t(11;14) positivity in HDM-treated AL
                      patients conferred superior CR rates and hemEFS. In view of
                      the reduced response of t(11;14) to bortezomib, this
                      highlights the impact of therapy on the prognostic role of
                      cytogenetic aberrations.},
      keywords     = {Immunoglobulin Light Chains (NLM Chemicals) / Melphalan
                      (NLM Chemicals)},
      cin          = {G330 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)G330-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27257181},
      doi          = {10.1182/blood-2015-10-676361},
      url          = {https://inrepo02.dkfz.de/record/125525},
}